Exhibit 12.1
Halozyme Therapeutics, Inc.
Statement of Ratios of Earnings to Fixed Charges and Preferred Stock Dividends
Year Ended December 31, | ||||||||||||||||||||
2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||||||
Earnings: | ||||||||||||||||||||
Net loss before income taxes | $ | (53,552 | ) | $ | (83,479 | ) | $ | (68,375 | ) | $ | (32,231 | ) | $ | (101,861 | ) | |||||
Add: fixed charges | 154 | 3,441 | 5,762 | 5,388 | 20,190 | |||||||||||||||
Earnings as defined | $ | (53,398 | ) | $ | (80,038 | ) | $ | (62,613 | ) | $ | (26,843 | ) | $ | (81,671 | ) | |||||
Fixed Charges and Preferred Stock Dividends: | ||||||||||||||||||||
Interest expense | $ | — | $ | 3,274 | $ | 5,581 | $ | 5,201 | $ | 19,977 | ||||||||||
Estimated interest component of rent expenses | 154 | 167 | 181 | 187 | 213 | |||||||||||||||
Total fixed charges | 154 | 3,441 | 5,762 | 5,388 | 20,190 | |||||||||||||||
Preferred stock dividends | — | — | — | — | — | |||||||||||||||
Total fixed charges and preferred stock dividends | $ | 154 | $ | 3,441 | $ | 5,762 | $ | 5,388 | $ | 20,190 | ||||||||||
Ratio of earnings to fixed charges | — | — | — | — | — | |||||||||||||||
Ratio of earnings to combined fixed charges and preferred stock dividends | — | — | — | — | — |